<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">genort</journal-id><journal-title-group><journal-title xml:lang="ru">Гений ортопедии</journal-title><trans-title-group xml:lang="en"><trans-title>Genij Ortopedii</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1028-4427</issn><issn pub-type="epub">2542-131X</issn><publisher><publisher-name>ЦЕНТР ИЛИЗАРОВА</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18019/1028-4427-2025-31-2-210-217</article-id><article-id custom-type="elpub" pub-id-type="custom">genort-3208</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Оригинальные статьи</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Original articles</subject></subj-group></article-categories><title-group><article-title>Способ прогнозирования исхода оперативного лечения пациентов с контрактурой Дюпюитрена на основе показателей лейкоформулы</article-title><trans-title-group xml:lang="en"><trans-title>Method of predicting the outcome of surgical treatment in Dupuytren's contractur based on leukocyte formula indices</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9914-8563</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Щудло</surname><given-names>Н. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Shchudlo</surname><given-names>N. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Наталья Анатольевна Щудло — доктор медицинских наук, ведущий научный сотрудник</p><p>Курган</p></bio><bio xml:lang="en"><p>Natalya A. Shchudlo — Doctor of Medical Sciences, Leading Researcher of the Experimental Laboratory</p><p>Kurgan</p></bio><email xlink:type="simple">nshchudlo@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сбродова</surname><given-names>Л. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Sbrodova</surname><given-names>L. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Людмила Ивановна Сбродова — кандидат биологических наук, научный сотрудник</p><p>Курган</p></bio><bio xml:lang="en"><p>Lyudmila I. Sbrodova — Candidate of Biological Sciences, Researcher</p><p>Kurgan</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4399-2973</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Останина</surname><given-names>Д. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Ostanina</surname><given-names>D. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Дарья Андреевна Останина — врач — травматолог-ортопед</p><p>Курган</p></bio><bio xml:lang="en"><p>Daria A. Ostanina — orthopaedic surgeon</p><p>Kurgan</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Национальный медицинский исследовательский центр травматологии и ортопедии имени академика Г.А. Илизарова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Ilizarov National Medical Research Centre for Traumatology and Orthopedics</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>21</day><month>04</month><year>2025</year></pub-date><volume>31</volume><issue>2</issue><fpage>210</fpage><lpage>217</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Щудло Н.А., Сбродова Л.И., Останина Д.А., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Щудло Н.А., Сбродова Л.И., Останина Д.А.</copyright-holder><copyright-holder xml:lang="en">Shchudlo N.A., Sbrodova L.I., Ostanina D.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.ilizarov-journal.com/jour/article/view/3208">https://www.ilizarov-journal.com/jour/article/view/3208</self-uri><abstract><sec><title>Введение</title><p>Введение. Данные мировой литературы свидетельствуют об актуальности прогнозирования исходов лечения пациентов с контрактурой Дюпюитрена (КД), в том числе на основе лабораторных методов. Сравнительные исследования результатов оперативного лечения при КД в зависимости от дооперационных показателей периферической крови в доступной литературе отсутствуют.</p><p>Цель работы — выявить возможные отличия предоперационных лейкоцитограмм пациентов с КД с различными исходами оперативного лечения через год после операции и оценить их прогностическую значимость.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Проведён анализ историй болезни 52 пациентов с КД, прооперированных в  клинике хирургии кисти Центра Илизарова в период 2021–2022 гг. Результаты оценены по шкале P.S. Khan, а также путём вычисления индекса редукции контрактуры (ИРКД). К группе 1 (n = 41) отнесены пациенты с удовлетворительными и неудовлетворительными результатами, остальные пациенты с хорошими и отличными результатами вошли в группу 2 (n = 41).</p></sec><sec><title>Результаты</title><p>Результаты. По значениям ИРКД группы оказались в непересекающихся диапазонах. Процентное содержание эозинофилов и базофилов (B + E) в группе 1 было больше, чем в группе 2 (p &lt; 0,05). ROC‑анализ модели «ИРКД — (B + E)» выявил площадь под кривой более 0,7 при p &lt; 0,01, специфичность 100 %, чувствительность менее 60 %. У пациентов с (B + E) &lt; 1,2 % частота отличных и хороших результатов через год после операции составляла 95,23 %, при (B + E) ≥ 1,2 % — 70,00 % (p &lt; 0,05).</p></sec><sec><title>Обсуждение</title><p>Обсуждение. Роль эозинофилов и базофилов в развитии фасциального фиброматоза неизвестна, однако установлено, что интерлейкины IL-4 и IL-13, секретируемые тучными клетками, базофилами и эозинофилами, вносят непосредственный вклад в активацию миофибробластов и развитие фиброза.</p></sec><sec><title>Заключение</title><p>Заключение. При (B + E) &lt; 1,2 % прогнозируется благоприятный исход как открытых, так и малоинвазивных оперативных вмешательств; при (B + E) ≥ 1,2 % высока вероятность прогрессирующего послеоперационного фиброзирования, что обосновывает выбор радикальных открытых вмешательств (гиподермофасциэктомии или дермофасциэктомии) и применение антифибротической терапии в послеоперационном периоде.</p></sec></abstract><trans-abstract xml:lang="en"><p>Introduction World literature indicates the relevance of predicting the outcomes of Dupuytren's contracture (DC) treatment, including those based on laboratory methods. There are no comparative studies of the results of surgical DC treatment based on preoperative peripheral blood counts in the available literature. The purpose of the work was to identify possible differences in preoperative leukocyte counts in DC with  different outcomes of surgical treatment one year after surgery and to evaluate their prognostic significance.</p><p>Materials and methods The analysis of medical records of 52 DC patients operated on in the Hand Surgery Clinic of the Ilizarov Center in 2021–2022 was conducted. The results were assessed using the Khan scale, as well as by calculating the contracture reduction index (CRI). The subgroup included 111 patients with fair and poor results, the remaining 41 were included in subgroup 2 with good and excellent results.</p><p>Results According to the CRI values, the subgroups were in non-overlapping ranges. The percentage of eosinophils and basophils (B + E) in subgroup 1 was higher than in subgroup 2 (p &lt; 0.05). ROC analysis of the "CRI — (B + E)" model revealed an area under the curve of more than 0.7 at p &lt; 0.01, specificity of 100 %, sensitivity of less than 60 %. In patients with (B + E) &lt; 1.2 %, the rate of excellent and good results one year after surgery was 95.23 %, with (B + E) ≥ 1.2 % 70.00 % (p &lt; 0.05).</p><p>Discussion The role of eosinophils and basophils in the development of fascial fibromatosis is unknown, but it has been established that interleukins IL-4 and IL-13 secreted by mast cells, basophils and eosinophils directly contribute to the activation of myofibroblasts and the development of fibrosis.</p><p>Conclusion In (B + E) &lt; 1.2 %, a favorable outcome is predicted for both open and minimally invasive surgeries; at (B + E) ≥ 1.2 % there is a high probability of progressive postoperative fibrosis, which justifies the choice of radical open interventions (hypodermectomy or dermofasciectomy) and the use of antifibrotic therapy in the postoperative period.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>контрактура Дюпюитрена</kwd><kwd>базофилы</kwd><kwd>эозинофилы</kwd><kwd>дооперационное прогнозирование</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Dupuytren's contracture</kwd><kwd>basophils</kwd><kwd>eosinophils</kwd><kwd>preoperative prognosis</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Научная работа финансирована в рамках государственного задания 2021–2023 гг.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Вишневский В.А. Контрактура Дюпюитрена кисти и её медико-социальная экспертиза. Запорожский медицинский журнал. 2014;(1):9-12.</mixed-citation><mixed-citation xml:lang="en">Вишневский В.А. Контрактура Дюпюитрена кисти и её медико-социальная экспертиза. Запорожский медицинский журнал. 2014;(1):9-12.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Rydberg M, Zimmerman M, Löfgren JP, et al. Metabolic factors and the risk of Dupuytren's disease: data from 30,000 individuals followed for over 20 years. Sci Rep. 2021;11(1):14669. doi: 10.1038/s41598-021-94025-7.</mixed-citation><mixed-citation xml:lang="en">Rydberg M, Zimmerman M, Löfgren JP, et al. Metabolic factors and the risk of Dupuytren's disease: data from 30,000 individuals followed for over 20 years. Sci Rep. 2021;11(1):14669. doi: 10.1038/s41598-021-94025-7.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Dutta A, Jayasinghe G, Deore S, et al. Dupuytren's Contracture - Current Concepts. J Clin Orthop Trauma. 2020;11(4):590-596. doi:10.1016/j.jcot.2020.03.026.</mixed-citation><mixed-citation xml:lang="en">Dutta A, Jayasinghe G, Deore S, et al. Dupuytren's Contracture - Current Concepts. J Clin Orthop Trauma. 2020;11(4):590-596. doi:10.1016/j.jcot.2020.03.026.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">van Rijssen AL, Ter Linden H, Werker PMN. Five-year results of a randomized clinical trial on treatment in Dupuytren's disease: percutaneous needle fasciotomy versus limited fasciectomy. Plast Reconstr Surg. 2012;129(2):469-477. doi: 10.1097/PRS.0b013e31823aea95.</mixed-citation><mixed-citation xml:lang="en">van Rijssen AL, Ter Linden H, Werker PMN. Five-year results of a randomized clinical trial on treatment in Dupuytren's disease: percutaneous needle fasciotomy versus limited fasciectomy. Plast Reconstr Surg. 2012;129(2):469-477. doi: 10.1097/PRS.0b013e31823aea95.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Микусев Г.И., Магомедов Р.О., Микусев И.Е., Байкеев Р.Ф. Болезнь Дюпюитрена: эпидемиология, особенности клиники и тактика хирургического лечения. Общественное здоровье и здравоохранение. 2013;(3):46-50.</mixed-citation><mixed-citation xml:lang="en">Микусев Г.И., Магомедов Р.О., Микусев И.Е., Байкеев Р.Ф. Болезнь Дюпюитрена: эпидемиология, особенности клиники и тактика хирургического лечения. Общественное здоровье и здравоохранение. 2013;(3):46-50.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Mikusev G.I., Baikeev R.F., Magomedov R.O., et al. Prognosis of long-term postoperative complications after surgical treatment of Dupuytren's disease (contracture). Research J. Pharm. and Tech. 2019;12(3):1055-1065. doi: 10.5958/0974-360X.2019.00174.4.</mixed-citation><mixed-citation xml:lang="en">Mikusev G.I., Baikeev R.F., Magomedov R.O., et al. Prognosis of long-term postoperative complications after surgical treatment of Dupuytren's disease (contracture). Research J. Pharm. and Tech. 2019;12(3):1055-1065. doi: 10.5958/0974-360X.2019.00174.4.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Neumüller J, Menzel J, Millesi H. Prevalence of HLA-DR3 and autoantibodies to connective tissue components in Dupuytren's contracture. Clin Immunol Immunopathol. 1994;71(2):142-148. doi: 10.1006/clin.1994.1064.</mixed-citation><mixed-citation xml:lang="en">Neumüller J, Menzel J, Millesi H. Prevalence of HLA-DR3 and autoantibodies to connective tissue components in Dupuytren's contracture. Clin Immunol Immunopathol. 1994;71(2):142-148. doi: 10.1006/clin.1994.1064.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Pereira RS, Black CM, Turner SM, Spencer JD. Antibodies to collagen types I-VI in Dupuytren's contracture. J Hand Surg Br. 1986;11(1):58-60. doi: 10.1016/0266-7681(86)90014-8.</mixed-citation><mixed-citation xml:lang="en">Pereira RS, Black CM, Turner SM, Spencer JD. Antibodies to collagen types I-VI in Dupuytren's contracture. J Hand Surg Br. 1986;11(1):58-60. doi: 10.1016/0266-7681(86)90014-8.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Wilkinson JM, Davidson RK, Swingler TE, et al. MMP-14 and MMP-2 are key metalloproteases in Dupuytren's disease fibroblastmediated contraction. Biochim Biophys Acta. 2012;1822(6):897-905. doi: 10.1016/j.bbadis.2012.02.001.</mixed-citation><mixed-citation xml:lang="en">Wilkinson JM, Davidson RK, Swingler TE, et al. MMP-14 and MMP-2 are key metalloproteases in Dupuytren's disease fibroblastmediated contraction. Biochim Biophys Acta. 2012;1822(6):897-905. doi: 10.1016/j.bbadis.2012.02.001.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Iqbal SA, Hayton MJ, Watson JS, et al. First identification of resident and circulating fibrocytes in Dupuytren's disease shown to be inhibited by serum amyloid P and Xiapex. PLoS One. 2014;9(6):e99967. doi: 10.1371/journal.pone.0099967.</mixed-citation><mixed-citation xml:lang="en">Iqbal SA, Hayton MJ, Watson JS, et al. First identification of resident and circulating fibrocytes in Dupuytren's disease shown to be inhibited by serum amyloid P and Xiapex. PLoS One. 2014;9(6):e99967. doi: 10.1371/journal.pone.0099967.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Johnston P, Larson D, Clark IM, Chojnowski AJ. Metalloproteinase gene expression correlates with clinical outcome in Dupuytren's disease. J Hand Surg Am. 2008;33(7):1160-1167. doi: 10.1016/j.jhsa.2008.04.002.</mixed-citation><mixed-citation xml:lang="en">Johnston P, Larson D, Clark IM, Chojnowski AJ. Metalloproteinase gene expression correlates with clinical outcome in Dupuytren's disease. J Hand Surg Am. 2008;33(7):1160-1167. doi: 10.1016/j.jhsa.2008.04.002.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Jupp O, Pullinger M, Marjoram T, et al. Biomarkers of Postsurgical Outcome in Dupuytren Disease. In: Werker P, Dias J, Eaton C, et al. (eds). Dupuytren Disease and Related Diseases - The Cutting Edge. Springer International Publ.; 2017:55-61. doi: 10.1007/978-3-319-32199-8_7.</mixed-citation><mixed-citation xml:lang="en">Jupp O, Pullinger M, Marjoram T, et al. Biomarkers of Postsurgical Outcome in Dupuytren Disease. In: Werker P, Dias J, Eaton C, et al. (eds). Dupuytren Disease and Related Diseases - The Cutting Edge. Springer International Publ.; 2017:55-61. doi: 10.1007/978-3-319-32199-8_7.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Hurst L. Dupuytren's fasciectomy: zig-zag-plasty technique. In: Blair WF (ed.). Techniques in Hand Surgery. Baltimore: Williams and Wilkins; 1996:518-529.</mixed-citation><mixed-citation xml:lang="en">Hurst L. Dupuytren's fasciectomy: zig-zag-plasty technique. In: Blair WF (ed.). Techniques in Hand Surgery. Baltimore: Williams and Wilkins; 1996:518-529.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">McFarlane RM. Some observations on the epidemiology of Dupuytren's disease. In: Hueston JT, Tubiana R. (eds). Dupuytren's Disease. London: Churchill Livingstone; 1985:122-128.</mixed-citation><mixed-citation xml:lang="en">McFarlane RM. Some observations on the epidemiology of Dupuytren's disease. In: Hueston JT, Tubiana R. (eds). Dupuytren's Disease. London: Churchill Livingstone; 1985:122-128.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Khan PS, Iqbal S, Zaroo I, Hayat H. Surgical Treatment of Dupuytren's Contracture; Results and Complications of Surgery: Our Experience. J Hand Microsurg. 2010;2(2):62-66. doi: 10.1007/s12593-010-0019-2.</mixed-citation><mixed-citation xml:lang="en">Khan PS, Iqbal S, Zaroo I, Hayat H. Surgical Treatment of Dupuytren's Contracture; Results and Complications of Surgery: Our Experience. J Hand Microsurg. 2010;2(2):62-66. doi: 10.1007/s12593-010-0019-2.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Stepić N, Končar J, Rajović M. The influence of Dupuytren's disease fingers contracture degree on surgical treatment outcome. Vojnosanit Pregl. 2017;74(1):19-23. doi: 10.2298/VSP150331103S.</mixed-citation><mixed-citation xml:lang="en">Stepić N, Končar J, Rajović M. The influence of Dupuytren's disease fingers contracture degree on surgical treatment outcome. Vojnosanit Pregl. 2017;74(1):19-23. doi: 10.2298/VSP150331103S.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Radhamony NG, Nair RR, Sreenivasan S, et al. Residual deformity versus recurrence following Dupuytren's palmar fasciectomy-a long term follow-up of 142 cases. Ann Med Surg (Lond). 2022;73:103224. doi: 10.1016/j.amsu.2021.103224.</mixed-citation><mixed-citation xml:lang="en">Radhamony NG, Nair RR, Sreenivasan S, et al. Residual deformity versus recurrence following Dupuytren's palmar fasciectomy-a long term follow-up of 142 cases. Ann Med Surg (Lond). 2022;73:103224. doi: 10.1016/j.amsu.2021.103224.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Микусев И.Е. Причины и профилактика повторных операций при контрактуре Дюпюитрена. Казанский медицинский журнал. 1995;76(5):384-387. doi: 10.17816/kazmj87154.</mixed-citation><mixed-citation xml:lang="en">Микусев И.Е. Причины и профилактика повторных операций при контрактуре Дюпюитрена. Казанский медицинский журнал. 1995;76(5):384-387. doi: 10.17816/kazmj87154.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Miyake K, Ito J, Karasuyama H. Role of Basophils in a Broad Spectrum of Disorders. Front Immunol. 2022;13:902494. doi: 10.3389/fimmu.2022.902494.</mixed-citation><mixed-citation xml:lang="en">Miyake K, Ito J, Karasuyama H. Role of Basophils in a Broad Spectrum of Disorders. Front Immunol. 2022;13:902494. doi: 10.3389/fimmu.2022.902494.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Valent P, Degenfeld-Schonburg L, Sadovnik I, et al. Eosinophils and eosinophil-associated disorders: immunological, clinical, and molecular complexity. Semin Immunopathol. 2021;43(3):423-438. doi: 10.1007/s00281-021-00863-y.</mixed-citation><mixed-citation xml:lang="en">Valent P, Degenfeld-Schonburg L, Sadovnik I, et al. Eosinophils and eosinophil-associated disorders: immunological, clinical, and molecular complexity. Semin Immunopathol. 2021;43(3):423-438. doi: 10.1007/s00281-021-00863-y.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Lombardi C, Berti A, Cottini M. The emerging roles of eosinophils: Implications for the targeted treatment of eosinophilic-associated inflammatory conditions. Curr Res Immunol. 2022;3:42-53. doi: 10.1016/j.crimmu.2022.03.002.</mixed-citation><mixed-citation xml:lang="en">Lombardi C, Berti A, Cottini M. The emerging roles of eosinophils: Implications for the targeted treatment of eosinophilic-associated inflammatory conditions. Curr Res Immunol. 2022;3:42-53. doi: 10.1016/j.crimmu.2022.03.002.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Wen T, Rothenberg ME. The regulatory function of eosinophils. Microbiol Spectrum. 2016;4(5):MCHD-0020-2015. doi: 10.1128/microbiolspec.MCHD-0020-2015.</mixed-citation><mixed-citation xml:lang="en">Wen T, Rothenberg ME. The regulatory function of eosinophils. Microbiol Spectrum. 2016;4(5):MCHD-0020-2015. doi: 10.1128/microbiolspec.MCHD-0020-2015.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Luca DC. Basophils. Pathology. Available from: https://www.pathologyoutlines.com/topic/bonemarrowbasophils.html. Accessed Oct 24, 2024.</mixed-citation><mixed-citation xml:lang="en">Luca DC. Basophils. Pathology. Available from: https://www.pathologyoutlines.com/topic/bonemarrowbasophils.html. Accessed Oct 24, 2024.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Shibuya R, Kim BS. Skin-homing basophils and beyond. Front Immunol. 2022;13:1059098. doi: 10.3389/fimmu.2022.1059098.</mixed-citation><mixed-citation xml:lang="en">Shibuya R, Kim BS. Skin-homing basophils and beyond. Front Immunol. 2022;13:1059098. doi: 10.3389/fimmu.2022.1059098.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Schubert TE, Weidler C, Borisch N, et al. Dupuytren's contracture is associated with sprouting of substance P positive nerve fibres and infiltration by mast cells. Ann Rheum Dis. 2006;65(3):414-415. doi: 10.1136/ard.2005.044016.</mixed-citation><mixed-citation xml:lang="en">Schubert TE, Weidler C, Borisch N, et al. Dupuytren's contracture is associated with sprouting of substance P positive nerve fibres and infiltration by mast cells. Ann Rheum Dis. 2006;65(3):414-415. doi: 10.1136/ard.2005.044016.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Щудло Н.А., Ступина Т.А., Варсегова Т.Н., Останина Д.А. Роль тучных клеток в прогрессировании контрактуры Дюпюитрена. Гений ортопедии. 2023;29(3):265-269. doi: 10.18019/1028-4427-2023-29-3-265-269. EDN: VLYUQJ.</mixed-citation><mixed-citation xml:lang="en">Щудло Н.А., Ступина Т.А., Варсегова Т.Н., Останина Д.А. Роль тучных клеток в прогрессировании контрактуры Дюпюитрена. Гений ортопедии. 2023;29(3):265-269. doi: 10.18019/1028-4427-2023-29-3-265-269. EDN: VLYUQJ.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Gessner A, Mohrs K, Mohrs M. Mast cells, basophils, and eosinophils acquire constitutive IL-4 and IL-13 transcripts during lineage differentiation that are sufficient for rapid cytokine production. J Immunol. 2005;174(2):1063-72. doi: 10.4049/jimmunol.174.2.1063.</mixed-citation><mixed-citation xml:lang="en">Gessner A, Mohrs K, Mohrs M. Mast cells, basophils, and eosinophils acquire constitutive IL-4 and IL-13 transcripts during lineage differentiation that are sufficient for rapid cytokine production. J Immunol. 2005;174(2):1063-72. doi: 10.4049/jimmunol.174.2.1063.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Gieseck RL 3rd, Wilson MS, Wynn TA. Type 2 immunity in tissue repair and fibrosis. Nat Rev Immunol. 2018;18(1):62-76. doi: 10.1038/nri.2017.90.</mixed-citation><mixed-citation xml:lang="en">Gieseck RL 3rd, Wilson MS, Wynn TA. Type 2 immunity in tissue repair and fibrosis. Nat Rev Immunol. 2018;18(1):62-76. doi: 10.1038/nri.2017.90.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Щудло Н.А., Сбродова Л.И., Останина Д.А. Диагностическая значимость лимфоцитарно-моноцитарного индекса при контрактуре Дюпюитрена. Гений ортопедии. 2023;29(4):382-387. doi: 10.18019/1028-4427-2023-29-4-382-387. EDN: IUGIXQ.</mixed-citation><mixed-citation xml:lang="en">Щудло Н.А., Сбродова Л.И., Останина Д.А. Диагностическая значимость лимфоцитарно-моноцитарного индекса при контрактуре Дюпюитрена. Гений ортопедии. 2023;29(4):382-387. doi: 10.18019/1028-4427-2023-29-4-382-387. EDN: IUGIXQ.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Щудло Н.А., Сбродова Л.И., Останина Д.А. Способ прогнозирования течения контрактуры Дюпюитрена для выбора тактики лечения. Патент РФ на изобретение № 2821473. 24.06.2024. Бюл. № 18. Доступно по: https://www.fips.ru/registers-doc-view/fips_servlet?DB=RUPAT&amp;rn=2563&amp;DocNumber=2821473&amp;TypeFile=html. Ссылка активна на 24.10.2024.</mixed-citation><mixed-citation xml:lang="en">Щудло Н.А., Сбродова Л.И., Останина Д.А. Способ прогнозирования течения контрактуры Дюпюитрена для выбора тактики лечения. Патент РФ на изобретение № 2821473. 24.06.2024. Бюл. № 18. Доступно по: https://www.fips.ru/registers-doc-view/fips_servlet?DB=RUPAT&amp;rn=2563&amp;DocNumber=2821473&amp;TypeFile=html. Ссылка активна на 24.10.2024.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Knobloch K, Redeker J, Vogt PM. Antifibrotic medication using a combination of N-acetyl-L-cystein (NAC) and ACE inhibitors can prevent the recurrence of Dupuytren's disease. Med Hypotheses. 2009;73(5):659-661. doi: 10.1016/j.mehy.2009.08.011.</mixed-citation><mixed-citation xml:lang="en">Knobloch K, Redeker J, Vogt PM. Antifibrotic medication using a combination of N-acetyl-L-cystein (NAC) and ACE inhibitors can prevent the recurrence of Dupuytren's disease. Med Hypotheses. 2009;73(5):659-661. doi: 10.1016/j.mehy.2009.08.011.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou C, Liu F, Gallo PH, et al. Anti-fibrotic action of pirfenidone in Dupuytren's disease-derived fibroblasts. BMC Musculoskelet Disord. 2016;17(1):469. doi: 10.1186/s12891-016-1326-y.</mixed-citation><mixed-citation xml:lang="en">Zhou C, Liu F, Gallo PH, et al. Anti-fibrotic action of pirfenidone in Dupuytren's disease-derived fibroblasts. BMC Musculoskelet Disord. 2016;17(1):469. doi: 10.1186/s12891-016-1326-y.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
